Report cover image

Global Graft Versus Host Disease Market Growth, Size, Trends Analysis- By Disease Type, By Treatment Type, By Age Group, Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Published Aug 01, 2025
Length 244 Pages
SKU # SPER20413961

Description

Graft Versus Host Disease Market Introduction and Overview

According to SPER market research, ‘Global Graft Versus Host Disease Market Size- By Disease Type, By Treatment Type, By Age Group, Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Graft Versus Host Disease Market is predicted to reach 6.84 Billion by 2034 with a CAGR 8.46%.

Graft Versus Host Disease (GVHD) is a complication that can arise after a bone marrow or stem cell transplant, where the donated immune cells (the graft) attack the recipient’s body (the host). This happens because the donor’s immune system identifies the recipient’s tissues as foreign and launches an immune response. GVHD can affect various organs, most commonly the skin, liver, and gastrointestinal tract, leading to symptoms such as skin rashes, liver issues, and digestive problems like diarrhea and stomach pain.

Restraints:
The graft versus host disease (GVHD) treatment market encounters several significant challenges that impact its growth. The disease’s complexity and variability in patient response make it difficult to establish standardized treatment protocols. A major hurdle is the limited availability of perfectly matched donors, which raises the risk of GVHD following transplants. Existing therapies often depend on immunosuppressants, which can cause severe side effects and weaken the immune system.

Global Graft Versus Host Disease Market Segmentation:

By Disease Type: Based on the Disease Type, Global Graft Versus Host Disease Market is segmented as; Acute graft versus host disease (aGVHD), Chronic graft versus host disease (cGVHD

By Treatment Type: Based on the Treatment Type, Global Graft Versus Host Disease Market is segmented as; Monoclonal antibodies, mTOR inhibitors, Tyrosine kinase inhibitors, Immunosuppressants, Corticosteroids, Other treatment types.

By Age Group: Based on the Age Group, Global Graft Versus Host Disease Market is segmented as; 20 years, 21-50 years, 51 years and above.

By Route of Administration: Based on the Route of Administration, Global Graft Versus Host Disease Market is segmented as; Oral, Intravenous, Topical.

By Distribution Channel: Based on the Distribution Channel, Global Graft Versus Host Disease Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.

By Region:
This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Table of Contents

244 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Graft Versus Host Disease Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Graft Versus Host Disease Market
7. Global Graft Versus Host Disease Market, By Disease Type, (USD Million) 2021-2034
7.1. Acute graft versus host disease (aGVHD)
7.2. Chronic graft versus host disease (cGVHD)
8. Global Graft Versus Host Disease Market, By Treatment Type, (USD Million) 2021-2034
8.1. Monoclonal antibodies
8.2. mTOR inhibitors
8.3. Tyrosine kinase inhibitors
8.4. Immunosuppressants
8.5. Corticosteroids
8.6. Other treatment types
9. Global Graft Versus Host Disease Market, By Age Group, (USD Million) 2021-2034
9.1.20 years
9.2.21-50 years
9.3.51 years and above
10. Global Graft Versus Host Disease Market, By Route of Administration, (USD Million) 2021-2034
10.1. Oral
10.2. Intravenous
10.3. Topical
11. Global Graft Versus Host Disease Market, By Distribution Channel, (USD Million) 2021-2034
11.1. Hospital pharmacies
11.2. Retail pharmacies
11.3. Online pharmacies
12. Global Graft Versus Host Disease Market, (USD Million) 2021-2034
12.1. Global Graft Versus Host Disease Market Size and Market Share
13. Global Graft Versus Host Disease Market, By Region, 2021-2034 (USD Million)
13.1. Asia-Pacific
13.1.1. Australia
13.1.2. China
13.1.3. India
13.1.4. Japan
13.1.5. South Korea
13.1.6. Rest of Asia-Pacific
13.2. Europe
13.2.1. France
13.2.2. Germany
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.2.6. Rest of Europe
13.3. Middle East and Africa
13.3.1. Kingdom of Saudi Arabia
13.3.2. United Arab Emirates
13.3.3. Qatar
13.3.4. South Africa
13.3.5. Egypt
13.3.6. Morocco
13.3.7. Nigeria
13.3.8. Rest of Middle-East and Africa
13.4. North America
13.4.1. Canada
13.4.2. Mexico
13.4.3. United States
13.5. Latin America
13.5.1. Argentina
13.5.2. Brazil
13.5.3. Rest of Latin America
14. Company Profile
14.1. Astellas Pharma Inc.
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. Bristol Myers Squibb
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. ElsaLys Biotech SA
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. Incyte Corporation
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. Johnson & Johnson Services, Inc.
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. Kiadis Pharma
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Mallinckrodt Pharmaceuticals
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Merck & Co., Inc.
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. Mesoblast Ltd.
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Neovii Pharmaceuticals AG
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. Novartis AG
14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary
14.11.4. Recent developments
14.12. Pfizer Inc.
14.12.1. Company details
14.12.2. Financial outlook
14.12.3. Product summary
14.12.4. Recent developments
14.13. Sanofi
14.13.1. Company details
14.13.2. Financial outlook
14.13.3. Product summary
14.13.4. Recent developments
14.14. Soligenix
14.14.1. Company details
14.14.2. Financial outlook
14.14.3. Product summary
14.14.4. Recent developments
14.15. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.